Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.58 |
| ▸ | PPARG | P37231 | 6/20 | 0.56 |
| ▸ | PPARD | Q03181 | 5/20 | 0.56 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.54 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.54 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.54 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.54 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.54 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31023529 | 0.88 | POLB (0.57) | PPARAPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL31023598 | 0.87 | PPARD (0.56) | PPARAPPARDMAPTPOLB | |
| SCHEMBL31023482 | 0.83 | SMN1; SMN2 (0.55) | PPARAPPARGPOLB | |
| SCHEMBL31275428 | 0.80 | MAPT (0.46) | MAPTPOLB | |
| SCHEMBL31023511 | 0.79 | EGLN1 (0.54) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL31023603 | 0.78 | HPGDS (0.49) | PPARAPPARG | |
| SCHEMBL4663813 | 0.77 | HPGD (0.72) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL31023570 | 0.77 | ROCK2 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL31023583 | 0.76 | PPARA (0.47) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL5974498 | 0.76 | PPARA (0.72) | PPARAPPARGPPARDPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027096-A1 | PHD INHIBITORS | UNIV OXFORD INNOVATION LTD (GB) | 2026-01-29 | — | — | US | disclosed |
| EP-4655294-A1 | PYRAZOLE DERIVSTIVES AS PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | disclosed |
| EP-4655288-A1 | PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024157019-A1 | PHD INHIBITORS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024157014-A1 | PYRAZOLE DERIVSTIVES AS PHD INHIBITORS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027096-A1 | PHD INHIBITORS | HIF1AN, HIF1A, EGLN1 | PPARA 2435/4885PPARG 1920/4885PPARD 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.